This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Aethlon Medical (AEMD) Note: Since September 30th, 2011 / Thank You Shareholders





SAN DIEGO, Feb. 5, 2013 /PRNewswire/ --  Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

In our quest to innovate life-saving therapeutics, we have persevered through untold challenges to create a single medical device that offers to optimize the benefit of cancer and infectious disease therapies.   As our endeavors transitioned beyond R&D, we thought we were cognizant of the entire alphabet soup of healthcare and financial regulatory agencies we would need to navigate to bring our technology to market.  

However, on September 30th 2011, we were blindsided by an action never anticipated.  The Depository Trust Company (DTC) eliminated the electronic transfer of our securities, otherwise known as a "DTC Chill."  As a result, broker-dealers across America began to restrict or prohibit trading in Aethlon Medical shares, which in turn reduced liquidity and inhibited the true sentiment for our company to be accurately reflected by the public markets.  A recently published viewpoint of a securities law firm provides a more succinct perspective on a DTC Chill:   

"The Depository Trust Company is the only stock depository in the U.S.  When DTC provides services as the depository for an issuer's securities, its securities can trade electronically. Without DTC eligibility, it is almost impossible for an issuer to establish an active market in its securities."

As the result of protracted legal effort, DTC has agreed to lift the restriction on the electronic transfer of our securities, which we reported in an SEC filing on January 7th.  In a related event, I am pleased to inform shareholders and other interested parties that our transfer agent has notified us that the CUSIP underlying our shares is now unlocked to again allow for our shares to be electronically traded on the DTC system. Thus, signaling the end of a lengthy and disheartening challenge faced by our organization.

While we cannot measure the full impact the DTC Chill, I ask you to consider some of our milestone achievements since September 30th, 2011. Milestone achievements that many biotechnology or medical device organizations would envy.

On the day (yes, the exact same day) the DTC Chill went into effect, we transitioned from a development-stage to revenue-stage organization as the result of a $6.8 Department of Defense (DOD) contract award from the Defense Advanced Research Projects Agency (DARPA).  Since contract initiation, we have generated in excess of $2 million in revenues and have advanced the development of a device and blood processing system to combat sepsis.  

Related to our DARPA program, we teamed with two larger industry organizations to respond to a $25 million systems integrator contract opportunity.  The recipient of this contract has not yet been announced by DARPA.

We reported our first Hepatitis-C (HCV) efficacy data related to the use of our Hemopurifier® as an adjunct to optimize the benefit of standard of care drug therapy.  The results exceeded expectations as a three-treatment Hemopurifier® protocol was demonstrated to reduce viral load to undetectable levels in as little as seven days.  Since September 30 th, 2011, organizations with clinical stage adjunct therapies have been acquired for a much as $11 Billion.

Based on prior discussions with the U.S. Food and Drug Administration (FDA), we established a protocol to elute the post-treatment biological fluid from the Hemopurifier® as a means to quantify HCV capture.  The result established an unprecedented data point validating the capture of up to 300 billion copies of HCV during a single treatment.  I plan to detail the relevance of this datapoint in a future CEO note.

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,302.32 +36.33 0.21%
S&P 500 2,010.91 -0.45 -0.02%
NASDAQ 4,574.1160 -19.3090 -0.42%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs